AstraZeneca PLC (NASDAQ:AZN) Stock Position Raised by Oak Ridge Investments LLC

Oak Ridge Investments LLC lifted its position in AstraZeneca PLC (NASDAQ:AZN) by 5.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 143,973 shares of the company’s stock after buying an additional 7,341 shares during the quarter. AstraZeneca accounts for about 0.7% of Oak Ridge Investments LLC’s investment portfolio, making the stock its 29th biggest holding. Oak Ridge Investments LLC’s holdings in AstraZeneca were worth $9,433,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in AZN. McClarren Financial Advisors Inc. lifted its stake in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares during the last quarter. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca during the 3rd quarter valued at $28,000. Ashton Thomas Securities LLC acquired a new stake in shares of AstraZeneca in the 3rd quarter valued at $45,000. Hollencrest Capital Management boosted its holdings in AstraZeneca by 38.4% in the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after purchasing an additional 192 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in AstraZeneca by 2,618.5% during the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after buying an additional 707 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AZN opened at $66.60 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock’s 50 day moving average price is $66.11 and its two-hundred day moving average price is $74.49. The firm has a market capitalization of $206.50 billion, a P/E ratio of 31.87, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter last year, the company posted $0.87 earnings per share. On average, equities analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on AZN. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.